Clinical Trials Directory

Trials / Completed

CompletedNCT01321957

Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer

FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
250 (actual)
Sponsor
Martin-Luther-Universität Halle-Wittenberg · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The primary objective of this study is to evaluate the efficacy of Irinotecan in combination with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of patients with metastatic colorectal cancer.

Detailed description

5-Fluorouracil and oxaliplatin (FOLFOX-Regimen) in combination with bevacizumab is regarded as standard first-line treatment in metastatic colorectal cancer \[Saltz et al., 2008\]. Current studies established the role of the FOLFOXIRI regimen \[Souglakos et al., 2006, Falcone et al., 2007\]. A further intensification of the therapy seems feasible yielding response rates up to 84% and a disease control rate up to 100% \[Falcone, 2008, Santomaggio, 2009, Masi, 2010\]. This trial evaluates the activity of an intensified first-line therapy for metastatic colorectal cancer compared to standard treatment.

Conditions

Interventions

TypeNameDescription
DRUGOxaliplatin, 5FU/LV, Bevacizumabbevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
DRUG5FU/LV, Oxaliplatin, Bevacizumab, Irinotecanbevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)

Timeline

Start date
2011-05-01
Primary completion
2016-09-01
Completion
2018-08-15
First posted
2011-03-24
Last updated
2018-10-25

Locations

51 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT01321957. Inclusion in this directory is not an endorsement.